Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $275.1 million.

  • Madrigal Pharmaceuticals' Change in Acquisitions & Divestments rose 2828.45% to $275.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 6980.26%. This contributed to the annual value of $863.3 million for FY2024, which is 15893.47% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Change in Acquisitions & Divestments is $275.1 million, which was up 2828.45% from $273.4 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Change in Acquisitions & Divestments peaked at $302.4 million during Q4 2024, and registered a low of $12.0 million during Q1 2023.
  • In the last 5 years, Madrigal Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $113.8 million in 2023 and averaged $146.3 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Change in Acquisitions & Divestments crashed by 8717.94% in 2023, and later soared by 142261.32% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Change in Acquisitions & Divestments stood at $70.5 million in 2021, then rose by 12.33% to $79.2 million in 2022, then soared by 43.69% to $113.8 million in 2023, then skyrocketed by 165.75% to $302.4 million in 2024, then decreased by 9.05% to $275.1 million in 2025.
  • Its last three reported values are $275.1 million in Q3 2025, $273.4 million for Q2 2025, and $294.7 million during Q1 2025.